title: Variation in management of immune suppression after allogeneic hematopoietic cell transplantation.
abstract: Practice variation in transplant physician management of immune suppression (IS) after allogeneic hematopoietic cell transplantation (HCT) is anticipated to have important consequences, but has not been characterized to date. We conducted a national survey of transplant physician members of the American Society for Blood and Marrow Transplantation to discern variation in IS management, characterize the burden of graft-versus-host disease (GVHD) emerging in the setting of IS taper, and describe the proportion of HCT recipients who successfully discontinue IS by 2 and 5 years post-HCT. There was marked heterogeneity in IS discontinuation practice, with variation in initiation of taper, sequence of agents tapered, frequency of changes, and strategy utilized. Twenty-five percent reported no consistent strategy in their usual practice. Confidence in therapeutic decision making was limited. The majority indicated that they could not predict who would develop GVHD on taper of IS, and reported a resultant burden of both acute and chronic GVHD (aGVHD, cGVHD) emerging or recurring in the setting of IS taper. HCT physicians projected rates of IS discontinuation that increased from 2 to 5 years post-HCT, and differed significantly according to donor relation and stem cell source utilized. The marked variation in practice, burden of GVHD emerging in the setting of IS taper, and limited confidence in therapeutic decision making all highlight shortcomings in an essential component of HCT physicians' scope of practice. These data argue for more rigorous study of IS management post-HCT so that evidence-based practice guidelines can be developed.
authors: Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida 33612, USA. joseph.pidala@moffitt.org
authors: Joseph
authors: J
authors: Pidala
authors: Stephanie J
authors: SJ
authors: Lee
authors: Gwen
authors: G
authors: Quinn
authors: Heather
authors: H
authors: Jim
authors: Jongphil
authors: J
authors: Kim
authors: Claudio
authors: C
authors: Anasetti
mesh_terms: D019317:Evidence-Based Medicine; D005260:Female; D006086:Graft vs Host Disease; D019983:Guideline Adherence; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D017410:Practice Guidelines as Topic; D011795:Surveys and Questionnaires; D013997:Time Factors; D014184:Transplantation, Homologous; D014481:United States